$2.5 Trillion in PE Dry Powder. Dental Practices Are on the Menu.

$2.5 trillion in PE dry powder. Dental practices are on the menu.

private equity has $2.5 trillion sitting idle, waiting to deploy. Dental remains the #1 target for PE because the unit economics are simple: patient lifetime value, predictable reimbursement, and operators who understand practice management.

But here's what changed: valuations aren't where they were in 2022. Buyers are now demanding 35-40% EBITDA margins as entry price. If your practice isn't there, you're not attractive. If you are, you're getting calls.

The practice owner sitting at 25% margin thinks they're doing fine. They're wrong. They're leaving $750K on the table per million in revenue if the market benchmark is 35%. PE knows this. They're not interested in fixing culture or operations - they're interested in cost structure.

If you're thinking about exit in the next 24 months, tighten labor costs, reduce supplier waste, and push case acceptance now. The next 90 days will determine whether your practice is a PE asset or a practice that has to stay independent and compete harder.

The money is coming. The question is whether you'll be ready to catch it.

Why PE Loves Dental (And Why That's About To Change)

Private equity firms have poured $45 billion into dental acquisitions since 2018. The thesis is straightforward: buy fragmented practices, consolidate operations, cut redundant overhead, and extract 300-500 basis points of margin improvement. Then sell the consolidated platform to a bigger PE firm at 8-10x EBITDA.

It worked beautifully from 2018-2022. Valuations climbed. Multiples expanded. Everyone made money. Then interest rates spiked. Debt financing costs doubled. Suddenly, a used buyout at 9x EBITDA with 7% interest doesn't pencil out like it did at 3% interest.

What happened? PE firms stopped buying practices at peak multiples. They started demanding better unit economics. If you're a $2M practice with 30% EBITDA ($600K), you're no longer attractive at 8x ($4.8M). The buyer has to borrow $3.5M+ at 7-8% interest ($245K annually), which eats half your EBITDA before they've done anything. No deal.

But if you're a $2M practice with 40% EBITDA ($800K), now the math works. The buyer borrows the same amount, but your cash flow covers debt service and leaves $555K for operations and growth. That's a deal.

The 35-40% EBITDA Threshold Is Real

Industry data from PE-backed DSO platforms shows the new floor: 35% EBITDA minimum for acquisition consideration. High-performing practices at 40%+ get premium multiples (7-8x). Practices below 30% are ignored entirely or bought at steep discounts (4-5x).

Translation: If you're serious about exit, you have 18-24 months to get your EBITDA above 35%. That means reducing labor costs from 35% to 30% of revenue. Cutting supply waste from 8% to 6%. Improving case acceptance to boost production per patient visit. And eliminating low-margin procedures that don't justify chair time.

The practice owners who think they can sell at 25% EBITDA and let the buyer "fix it" are delusional. PE doesn't buy projects. They buy cash flow. If you're not generating it, they're not buying.

OPERATOR MATH

Let's model two practices, both doing $2M annual production, both considering exit in 2026.

Practice A: 25% EBITDA (current state)
Revenue: $2M
Labor: $700K (35%)
Supplies: $160K (8%)
Rent: $240K (12%)
Other overhead: $400K (20%)
EBITDA: $500K (25%)

PE valuation at 5x multiple (low due to poor margins):
Exit value: $2.5M
After taxes and fees: ~$2M net to owner

Practice B: 38% EBITDA (optimized)
Revenue: $2M
Labor: $600K (30%, one FTE eliminated via AI receptionist + efficiency)
Supplies: $120K (6%, renegotiated supplier contracts)
Rent: $240K (12%, same)
Other overhead: $280K (14%, marketing optimized, waste eliminated)
EBITDA: $760K (38%)

PE valuation at 7.5x multiple (strong margins):
Exit value: $5.7M
After taxes and fees: ~$4.5M net to owner

Difference: $2.5M

That's what optimizing from 25% to 38% EBITDA does. It doesn't just increase cash flow. It multiplies your exit value by 2.3x. The work to get there - cutting one FTE, renegotiating suppliers, tightening operations - takes 12-18 months. The payoff is $2.5M.

Cost of inaction:
If Practice A owner waits and sells at 25% EBITDA in 2027, they leave $2.5M on the table. If interest rates stay elevated and multiples compress further (5x drops to 4x), they leave $3M on the table.

THE TAKEAWAY

If you're considering exit in the next 24 months:

• Run an EBITDA audit today. Calculate your true EBITDA (not what you report to the IRS, what a buyer will calculate). If you're below 32%, you have work to do.
• Target 38% EBITDA as your exit goal. That's where premium multiples start. Every point above 35% adds $150K-300K to your exit value on a $2M practice.
• Cut labor first. It's your biggest lever. One FTE elimination (via AI, automation, or efficiency) saves $50K-70K annually and improves EBITDA 2.5-3.5 points.
• Renegotiate suppliers next. Consolidate vendors, demand better terms, switch to generics where clinically acceptable. Save 1-2 points of EBITDA.
• Stop low-margin procedures. If a procedure generates less than $200/hour in production and requires high-cost materials, eliminate it. Focus chair time on high-margin work.
• Hire a CPA with dental M&A experience. They'll model your EBITDA properly and show you where to optimize. Cost: $5K-10K. ROI: $500K-1M+ on exit value.

The PE money is real. The multiples are compressed but still attractive for high-performing practices. The window is open for another 18-24 months. If you're not optimizing now, you're leaving seven figures on the table.